Setbacks often have a much larger effect on share prices at developmental companies than more established ones. While the investment community has seen several lowly developing biotechs rise from the ashes, rushing into a position at a company that recently got whacked or is facing headwinds can be a dangerous venture. Here are a few such companies with concerns that should be major factors in any investing decisions. In other words, these are not the best biotech stocks on the market.
Arena Pharmaceuticals� (NASDAQ: ARNA )
^SPX data by YCharts.
Despite sky-high potential for its weight-loss pill, Belviq, Arena has not had an electrifying start out of the gate. Total prescriptions total just 1,087 for the week of June 14 and 1,829 the next, according to TheStreet's Adam Feuerstein. Investors knew it would be difficult to gain traction with doctors, but perhaps underestimated just how difficult. While it is still early in the game for Arena, consider that Orexigen estimates that the total obesity market supported nearly 8 million prescriptions in 2012. This company is crawling toward disrupting the status quo, and shares have been punished as a result. Things may not get much better in the near future after Consumer Reports gave Belviq a dismal review earlier this month. I would steer clear of Arena until the attitude toward weight-loss therapies improves.
5 Best Freight Stocks To Own For 2015: Nestle SA (NESN)
Nestle SA is a Swiss Company engaged in the nutrition, health and wellness sectors. It is the holding company of the Nestle Group, which comprises subsidiaries, associated companies and joint ventures throughout the world. It has such business units as Food and Beverage, Nestle Waters and Nestle Nutrition. It is also active in the pharmaceutical sector. It divides its products into Powdered and liquid beverages, Water, Milk products and Ice cream, Nutrition, Prepared dishes and cooking aids, Confectionery, PetCare and Pharmaceutical products. In February 2011, the Company acquired CM&D Pharma Ltd. Advisors' Opinion:- [By Corinne Gretler]
Swiss stocks fell for a second day, their first back-to-back losses this month, as Nestle (NESN) SA retreated after reporting slower growth in sales.
- [By Celeste Perri]
Nestle SA (NESN) is selling Givaudan (GIVN) SA shares worth $1.27 billion at yesterday�� closing price to institutional investors, winding down its stake in the world�� largest flavorings maker.
10 Best Integrated Utility Stocks To Own For 2014: Arch Coal Inc. (ACI)
Arch Coal, Inc. produces and sells thermal and metallurgical coal from surface and underground mines located in the United States. As of December 31, 2013, it operated or contracted out the operation of 22 mines, and owned or controlled approximately 5.3 billion tons of proven and probable recoverable reserves. The company also owned or controlled primarily through long-term leases approximately 32,135 acres of coal land in Ohio; 22,417 acres of coal land in Maryland; 46,532 acres of coal land in Virginia; 425,038 acres of coal land in West Virginia; 107,668 acres of coal land in Wyoming; 267,024 acres of coal land in Illinois; 19,428 acres of coal land in Montana; 21,802 acres of coal land in New Mexico; and 20,166 acres of coal land in Colorado, as well as coal land in Kentucky. In addition, it owned or controlled through long-term leases smaller parcels of property in Alabama, Indiana, Washington, Arkansas, California, Utah, and Texas. The company sells coal to power pl ants, steel mills, and industrial facilities. Arch Coal, Inc. was founded in 1969 and is headquartered in St. Louis, Missouri.
Advisors' Opinion:- [By Ben Levisohn]
When Goldman Sachs talks, people listen. So it’s odd to see Goldman upgrade Consol Energy (CNX) and for the coal miner to fall today. Even odder: Three coal stocks that were on the receiving end of price target cuts–Alpha Natural Resources (ANR), Arch Coal (ACI) and Walter Energy (WLT)–have gained. At least Peabody Energy (BTU), which Goldman cut, is falling.
10 Best Integrated Utility Stocks To Own For 2014: Active Power Inc.(ACPW)
Active Power, Inc., together with its subsidiaries, designs, manufactures, and markets critical power quality solutions. It provides various products that deliver continuous clean power; and protects customers from voltage fluctuations, such as surges and sags, and frequency fluctuations, as well as offer temporary power to bridge the gap between a power outage and the restoration of utility power. The company offers the CleanSource UPS, a battery free uninterruptible power supply (UPS) system that integrates UPS electronics and flywheel energy storage system into one compact cabinet. Active Power, Inc. also provides the CleanSource DC, a battery-free replacement for lead-acid batteries used for bridging power; CoolAir products; and GenSTART, a battery-free starting modular system for customer?s diesel generator. In addition, it offers continuous power systems, which incorporates its UPS products with switchgear and a generator sold in a containerized package, and markete d under the PowerHouse brand name. Further, the company provides customer support services, including infrastructure needs assessment, vetting and validation, alignment with business objectives, system design, deployment, and start-up and commissioning, as well as service, support, and monitoring. It serves data centers, manufacturing, technology, broadcast and communications, financial, utilities, healthcare, government, and airport industries. The company sells its products through direct sales force, manufacturer?s representatives, distributors, strategic IT partners, and original equipment manufacturer partners in the United States, Europe, the Middle East, Africa, the Asia Pacific, and North America. Active Power, Inc. was founded in 1992 and is headquartered in Austin, Texas.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 electrical components and equipment player that's starting to move within range of a near-term breakout trade is Active Power (ACPW), which designs, manufactures and markets power solutions that provide business continuity and protect customers in the event of an electrical power disturbance. Its products deliver clean power, protecting customers from voltage fluctuations. This stock has hasn't done much so far in 2013, with shares off by 6.7%.
If you take a look at the chart for Active Power, you'll notice that this stock recently formed a double bottom chart pattern at $2.82 to $2.80 a share. Since forming that bottom, shares of ACPW have started to uptrend and move back above its 50-day moving average of $2.94 a share. That move is quickly pushing shares of ACPW within range of triggering a near-term breakout trade.
Market players should now look for long-biased trades in ACPW if it manages to break out above some near-term overhead resistance levels at $3.14 to $3.23 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 87,166 shares. If that breakout hits soon, then ACPW will set up to re-test or possibly take its next major overhead resistance levels at $3.65 to $3.76 a share. Any high-volume move above those levels will then give ACPW a chance to tag its next major overhead resistance levels at $4 to $4.20, or even $4.50 a share.
Traders can look to buy ACPW off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average at $2.94 a share, or near its double bottom zone at $2.80 a share. One can also buy ACPW off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
10 Best Integrated Utility Stocks To Own For 2014: Amira Nature Foods Ltd (ANFI)
Amira Nature Foods Ltd., incorporated on February 20, 2012, is a provider of packaged Indian specialty rice, with sales in over 40 countries. It generates the majority of its revenue through the sale of Basmati rice, a long-grain rice grown only in certain regions of the Indian sub-continent. The Company sells its products, primarily in emerging markets, through a distribution network. It sells its Amira brand in more than 25 countries. The Company sells its Amira branded products to Indian retailers such as Bharti Wal-Mart, Big Bazaar, Metro Cash & Carry, Spar, Spencer's Retail, Star Bazaar (Tesco in India) and Total and retailers, such as Carrefour, Costco, Jetro Restaurant Depot, Lulu's and Smart & Final, and through the foodservice channel. It participates across the entire rice supply chain from the procurement of paddy to its storage, aging, processing into rice, packaging, distribution and marketing. In June 2013, the Company announced that it has launched Amira branded products in the United Kingdom. In January 2014, Amira Nature Foods Ltd acquired Basmati Rice GmbH.
The Company operates an automated and integrated processing and milling facility that is located in the vicinity of the key Basmati rice paddy producing regions of northern India. The facility spans a covered area of 310,221 square feet, with a processing capacity of 24 metric tons of paddy per hour. During the year ended March 31, 2012, 34% of its revenue was derived from sales in India, and 50.3% was derived from sales in the Europe, Middle East and Africa region, or EMEA, 14.3% was derived from sales in the Asia Pacific region, and 1.4% was derived from sales in North America.
Advisors' Opinion:- [By Tom Bishop]
Steve Halpern: One of your recent recommendations is a company that, really, was probably unknown to most investors. It's called Amira Nature Foods (ANFI) , which is a maker of premium rice. Can you tell us briefly about that?
- [By Garrett Cook]
Amira Nature Foods (NYSE: ANFI) shares shot up 12.76 percent to $14.67 after the company reported better-than-expected fourth-quarter earnings.
Shares of Global Eagle Entertainment (NASDAQ: ENT) got a boost, shooting up 10.38 percent to $12.12 after the company and Boeing (NYSE: BA) announced a satellite connectivity partnership.
10 Best Integrated Utility Stocks To Own For 2014: Resources Connection Inc.(RECN)
Resources Connection, Inc. provides professional services in the areas of finance, accounting, risk management and internal audit, corporate advisory, strategic communications and restructuring, information management, human capital, supply chain management, actuarial, and legal and regulatory services to support client-led projects and initiatives. It offers finance and accounting services, including financial analyses, budgeting and forecasting, audit preparation, public-entity reporting, tax-related projects, merger and acquisition due diligence, initial public offering assistance, and assistance in the preparation or restatement of financial statements; information management services, such as financial system/enterprise resource planning implementation, and post implementation optimization services; and corporate advisory, strategic communications, and restructuring services. The company also provides risk management and internal audit services comprising compliance r eviews, internal audit co-sourcing, and assistance services; supply chain management services, including strategic sourcing efforts, contract negotiations, and purchasing strategy services; and actuarial support services for pension and life insurance companies. In addition, it offers human capital services, such as change management, and compensation program design and implementation services; and legal and regulatory services comprising providing attorneys, paralegals, and contract managers to assist clients, such as law firms with project-based or peak period needs. Further, the company provides policyIQ, a Web-based content management product for documenting, managing, and communicating various types of business information, including policies and procedures, Sarbanes documentation, training documentation, and other business content. It operates in North America, Europe, and the Asia Pacific. The company was founded in 1996 and is headquartered in Irvine, California.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Resources Connection (Nasdaq: RECN ) , whose recent revenue and earnings are plotted below. - [By Jake L'Ecuyer]
Resources Connection (NASDAQ: RECN) shot up 7.38 percent to $15.29 after the company reported upbeat FQ2 earnings.
Rite Aid (NYSE: RAD) was also up, gaining 8.13 percent to $5.45 after the company reported a 2.9% gain in its December same-store sales.
- [By Monica Gerson]
Resources Connection (NASDAQ: RECN) is estimated to post its Q1 earnings at $0.12 per share on revenue of $133.43 million.
Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets
- [By Rich Smith]
On May 28, Irvine, Calif.-based Resources Connection (NASDAQ: RECN ) will be losing one chief executive officer, and gaining a new one.
10 Best Integrated Utility Stocks To Own For 2014: Salix Pharmaceuticals Ltd (SLXP)
Salix Pharmaceuticals, Ltd., incorporated on December 31, 2001, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�� products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.
Xifaxan (rifaximin) tablets
Xifaxan is a gastrointestinal-specific oral antibiotic. The Food and Drug Administration ( FDA) approved Xifaxan 200 milligram for the treatment of patients 12 years of age and older with travelers��diarrhea caused by noninvasive strains of E coli. Xifaxan 550 milligram was approved by the FDA for reduction in risk of overt hepatic encephalopathy (HE), recurrence in patients 18 years of age or older.
It launched Xifaxan 200milligram in the United States and Xifaxan 550 milligram using its own direct sales force. The Company is exploring potential additional indications, formulations, clinical trials and co-promotion arrangements to capitalize on the potential for Xifaxan, including its development program in irritable bowel syndrome.
In October 2012, the USPTO declared an interference action to determine the priority of invention between Cipla�� application related to amorphous rifaximin and Solmag SpA�� application directed to amorphous rifaximin. In February 2012, the FDA posted draft bioequivalence guidance for rifaximin 550 milligram tablets. The draft guidance for rifaximin 550 milligram tablets recommends that in addition to conducting the program outlined in the FDA posted ! draft guidance document for rifaximin 200 milligram tablets discussed above, a single-dose, three-way crossover in-vivo study of fasting bioequivalence with pharmacokinetic endpoints in both fasting and fed states be performed in the 550 milligram tablets. Additionally, the guidance stipulated that the formulation of the 550 milligram strength should be proportionally similar to that of the 200 milligram strength in order to file an ANDA for approval of a generic rifaximin 550 milligram tablet for the treatment of hepatic encephalopathy.
MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid) oral solution
MoviPrep is a patent-protected, liquid polyethylene glycol-salt, or PEG, bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations.
Apriso (mesalamine) extended-release capsules 0.375 gram
Apriso is a locally-acting aminosalicylate and is the only delayed and extended release mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product�� prolonged release mechanism might allow them to expand the range of treatment options for ulcerative colitis.
Relistor (methylnaltrexone bromide)
Relistor Subcutaneous Injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved for use in over 55 countries worldwide.
OsmoPrep and Visicol (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) tablets
Visicol and OsmoPrep tablets are indicated for clean! sing of t! he colon as a preparation for colonoscopy in adults 18 years of age or older. Visicol and OsmoPrep are the only, tablet bowel cleansing products approved by the FDA and marketed in the United States. OsmoPrep is a patented, second-generation tablet bowel cleansing product that the FDA approved. OsmoPrep offers potential benefits compared to Visico,l such as its lack of microcrystalline cellulose, smaller tablet size and possible lower dose administration.
Solesta
Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for surgery or anesthesia.
Deflux
Deflux is a medical device indicated for children affected by Grades II-IV vesicoureteral reflux, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. Deflux was granted premarket approval application (PMA) approval, and has been on the market in the United States.
Fulyzaq (crofelemer) delayed-release tablets
On December 31, 2012, the FDA granted marketing approval for this product, under the trade name Fulyzaq. Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration.
Giazo (balsalazide disodium) tablets
February 3, 2012, the FDA granted marketing approval for this product under the trade name Giazo. Giazo is indicated for the treatment of mildly to moderately active ulcerative col! itis in m! ale patients 18 years of age and older. It shipped Giazo to wholesalers in 2012.
Metozolv ODT (metoclopramide hydrochloride) 5 milligrams and 10 milligrams orally disintegrating tablets
METOZOLV ODT is indicated for the relief of symptomatic gastroesophageal reflux or short-term (4-12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and diabetic gastroparesis or the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis.
Azasan (azathioprine) tablets
Azasan is an FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. It launched the 75 and 100 milligrams dosage strengths of Azasan in the United States.
Anusol-HC and Proctocort (hydrocortisone) creams and suppositories
The Company acquired the right to sell Anusol-HC 2.5% (hydrocortisone USP) cream, Anusol-HC 25 milligrams (hydrocortisone acetate) rectal suppositories, Proctocort 1% (hydrocortisone USP) cream and Proctocort 30 mg (hydrocortisone acetate) rectal suppositories from King Pharmaceuticals, Inc. The two cream products are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. The two suppository products are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions.
Pepcid (famotidine) for Oral Suspension and Diuril (Chlorothiazide)
Pepcid Oral Suspension is a widely known prescription pharmaceutical product indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and gastro-esophageal reflux disease. Pepcid Oral Suspension and Diuril Oral Suspension, both liquid form! ulations ! of their solid dosage form counterparts, compete in a combined annual United States market concentrated in pediatric and hospitalized patient populations.
Colazal (balsalazide disodium) capsules
The Company launched Colazal to physicians in the United States. FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with ulcerative colitis. The pediatric use of Colazal has been granted orphan drug designation. The Office of Generic Drugs, or OGD, approved three generic balsalazide capsule products.
The Company competes with GlaxoSmithKline plc, Giuliani S.p.A., Axcan Pharma, Inc., Abbott Laboratories, Warner Chilcott plc, Shire Pharmaceuticals Group plc, Pharmacia & Upjohn, Inc., Alaven Pharmaceutical LLC, Ferring Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Cumberland Pharmaceuticals, Inc, Prometheus Laboratories, Inc., Ranbaxy Pharmaceuticals, Ferndale Laboratories, GATE Pharmaceuticals , Nycomed , Medtronic, Inc., and Cubist Pharmaceuticals, Inc.
Advisors' Opinion:- [By Eric Volkman]
McGraw-Hill Financial's S&P Dow Jones Indices is making several adjustments to a pair of its signature products. On July 30 after market close, the S&P MidCap 400 will be the new home of Salix Pharmaceuticals (NASDAQ: SLXP ) , which advances from the S&P SmallCap 600 to replace Gardner Denver (NYSE: GDI ) . The latter company agreed to be acquired by KKR earlier this month.
- [By Garrett Cook]
Salix Pharmaceuticals (NASDAQ: SLXP) shares shot up 12.54 percent to $138.82 as the company reported that endpoint was met in TARGET 3 study.
Shares of GoPro (NASDAQ: GPRO) got a boost, shooting up 15.19 percent to $46.71 following an announcement by the Chicago Board Options Exchange (CBOE) that it will list options for GoPro starting Monday, July 7. GoPro shares jumped 13.39% on Monday.
- [By David Williamson]
In this segment, health-care analyst David Williamson takes a look at the upcoming acquisition by Salix Pharmaceuticals (NASDAQ: SLXP ) of Santarus (NASDAQ: SNTS ) for about $2.6 billion. Salix is currently a maker of drugs for gastrointestinal diseases, and the immediately accretive deal will give Salix access to treatments for both diabetes and heartburn. Shares of both companies were up significantly on the news. David tells investors why shareholders should be pleased with this deal on both ends and what he thinks of the stock going forward.
- [By Garrett Cook]
Salix Pharmaceuticals (NASDAQ: SLXP) shares tumbled 3.01 percent to $133.15 after the company agreed to merge with a unit of Cosmo Pharmaceuticals SpA.
10 Best Integrated Utility Stocks To Own For 2014: Songbird Estates PLC (SBEPF.PK)
Songbird Estates plc is engaged in management of its investment in its main subsidiary, Canary Wharf Group plc (Canary Wharf Group), which is the holding company. Canary Wharf Group is engaged in integrated property development, investment and management focusing primarily on the Estate. In London, Canary Wharf Group is engaged through joint ventures in the redevelopment of 20 Fenchurch Street and the Shell Centre. Canary Wharf Group�� investment property portfolio consists of 16 completed properties (out of the approximately 35constructed on the Estate) totaling approximately seven meter square feet of net internal area (NIA). In July 2013, Songbird Estates plc's Canary Wharf Group plc completed the acquisition from Gort Limited (in administration) and Hibernia (2005) Limited (in administration), of 15 Westferry Circus at Canary Wharf. Advisors' Opinion:- [By Mike Arnold]
Brookfield's public assets include a 21% stake (and potentially more given certain warrants held by Brookfield) in General Growth Properties (GGP), a 51% stake in Brookfield Office Properties (BPO), a 36% stake (again, more if certain warrants are exercised) in Rouse Properties (RSE) and 21% stake in Canary Wharf Group Plc, which is majority owned by Songbird Estates Plc (SBEPF.PK).
No comments:
Post a Comment